← Back to Screener
ScreenerNewsCompareWatchlist
VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesNewsCompareWatchlist
AnalyzeValuationTotal ReturnDCA CalculatorInsider Activity

ABSI logoAbsci Corporation(ABSI)Earnings, Financials & Key Ratios

ABSI•NASDAQ
$5.95
$925M mkt cap·Price updated May 6, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryDrug Discovery and Antibody Platforms
AboutAbsci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.Show more
  • Revenue$3M-38.2%
  • EBITDA-$113M-18.3%
  • Net Income-$115M-11.7%
  • EPS (Diluted)-0.84+10.6%
  • Gross Margin-319.36%+75.0%
  • EBITDA Margin-4034.86%-91.6%
  • Operating Margin-4454.21%-85.5%
  • Net Margin-4113.68%-80.9%
  • ROE-62.5%-7.7%
  • ROIC-57.96%+5.0%
  • Debt/Equity0.03-50.4%
  • Interest Coverage-596.74-213.7%
Technical→

ABSI Key Insights

Absci Corporation (ABSI) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Company is almost debt free
  • ✓Momentum leader: RS Rating 92 (top 8%)
  • ✓Trading near 52-week high

✗Weaknesses

  • ✗Profits declining 51.7% over 5 years
  • ✗Negative free cash flow
  • ✗Sales declining 10.1% over 5 years
  • ✗Shares diluted 24.1% in last year
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

ABSI Price & Volume

Absci Corporation (ABSI) stock price & volume — 10-year historical chart

Loading chart...

ABSI Growth Metrics

Absci Corporation (ABSI) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years-10.14%
3 Years-21.31%
TTM-38.24%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-11.71%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM8.6%

Return on Capital

10 Years-43.31%
5 Years-47.17%
3 Years-57.54%
Last Year-65.9%

ABSI Recent Earnings

Absci Corporation (ABSI) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 1/12 qtrs (8%)●Beat Revenue 1/12 qtrs (8%)
Q2 2026Latest
Mar 24, 2026
EPS
$0.23
Est $0.16
-43.8%
Revenue
$650,000
Est $1M
-54.2%
Q4 2025
Nov 12, 2025
EPS
$0.20
Est $0.19
-5.3%
Revenue
$378,000
Est $1M
-72.6%
Q3 2025
Aug 12, 2025
EPS
$0.24
Est $0.19
-26.3%
Revenue
$593,000
Est $5M
-88.5%
Q2 2025
May 13, 2025
EPS
$0.21
Est $0.23
+8.7%
Revenue
$1M
Est $1M
-9.3%
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMar 24, 2026
$0.23vs $0.16-43.8%
$650,000vs $1M-54.2%
Q4 2025Nov 12, 2025
$0.20vs $0.19-5.3%
$378,000vs $1M-72.6%
Q3 2025Aug 12, 2025
$0.24vs $0.19-26.3%
$593,000vs $5M-88.5%
Q2 2025May 13, 2025
$0.21vs $0.23+8.7%
$1Mvs $1M-9.3%
Based on last 12 quarters of dataView full earnings history →

ABSI Peer Comparison

Absci Corporation (ABSI) competitors in Drug Discovery and Antibody Platforms — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
RXRX logoRXRXRecursion Pharmaceuticals, Inc.Direct Competitor1.53B3.43-2.3826.92%-8.44%-54.32%0.07
SDGR logoSDGRSchrödinger, Inc.Direct Competitor969.87M12.98-9.2123.29%-40.6%-30.85%0.30
ALIT logoALITAlight, Inc.Direct Competitor490.57M0.94-0.16-3%-137.5%-171.72%1.92
TWST logoTWSTTwist Bioscience CorporationProduct Competitor3.71B59.53-45.7920.32%-19.85%-17.46%0.29
BEAM logoBEAMBeam Therapeutics Inc.Product Competitor3.32B32.33-39.92120.01%-57.24%-7.31%0.24
NTLA logoNTLAIntellia Therapeutics, Inc.Product Competitor1.61B13.85-3.64-100%-61.47%0.14
CRSP logoCRSPCRISPR Therapeutics AGProduct Competitor5.31B55.08-8.51-89.97%-138.57%-30.88%0.21
ILMN logoILMNIllumina, Inc.Supply Chain21.66B142.5826.16-0.78%19.43%32.84%0.94

Compare ABSI vs Peers

Absci Corporation (ABSI) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs RXRX

Most directly comparable listed peer for ABSI.

Scale Benchmark

vs TMO

Larger-name benchmark to compare ABSI against a more recognizable public peer.

Peer Set

Compare Top 5

vs RXRX, SDGR, ALIT, TWST

ABSI Income Statement

Absci Corporation (ABSI) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
Line itemDec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25
Sales/Revenue2.06M4.78M4.78M5.75M5.72M4.53M2.8M
Revenue Growth %-132.04%0.04%20.18%-0.5%-20.71%-38.24%
Cost of Goods Sold011.45M44.59M58.91M47.57M62.46M11.74M
COGS % of Revenue-239.5%932.37%1025.02%831.88%1377.57%419.36%
Gross Profit
2.06M▲ 0%
-6.67M▼ 423.7%
-39.8M▼ 496.9%
-53.16M▼ 33.6%
-41.85M▲ 21.3%
-57.92M▼ 38.4%
-8.94M▲ 84.6%
Gross Margin %100%-139.5%-832.37%-925.02%-731.88%-1277.57%-319.36%
Gross Profit Growth %--423.69%-496.94%-33.56%21.28%-38.41%84.56%
Operating Expenses8.32M6.63M35.43M53.59M73.67M50.96M115.78M
OpEx % of Revenue404.13%138.77%740.99%932.47%1288.32%1124.02%4134.86%
Selling, General & Admin3.52M5.5M000035.06M
SG&A % of Revenue171.02%115.1%----1252.07%
Research & Development4.31M11.45M44.59M58.91M48.07M63.86M81.42M
R&D % of Revenue209.27%239.5%932.37%1025.02%840.63%1408.45%2907.79%
Other Operating Expenses491K-10.32M-9.15M-5.32M25.6M-12.9M-700K
Operating Income
-6.26M▲ 0%
-13.3M▼ 112.3%
-75.24M▼ 465.7%
-106.75M▼ 41.9%
-115.52M▼ 8.2%
-108.89M▲ 5.7%
-124.72M▼ 14.5%
Operating Margin %-304.13%-278.26%-1573.36%-1857.49%-2020.2%-2401.59%-4454.21%
Operating Income Growth %--112.31%-465.66%-41.88%-8.21%5.74%-14.54%
EBITDA-5.77M-12.17M-68.58M-93.71M-101.52M-95.5M-112.98M
EBITDA Margin %-280.29%-254.6%-1434.21%-1630.64%-1775.38%-2106.29%-4034.86%
EBITDA Growth %--110.77%-463.55%-36.64%-8.33%5.93%-18.3%
D&A (Non-Cash Add-back)491K1.13M6.65M13.04M14M13.39M11.74M
EBIT-6.32M-13.72M-74.34M-106.75M-93.68M-107.49M-124.72M
Net Interest Income-268K-634K-3.43M-972K-1.01M-565K-209K
Interest Income0000000
Interest Expense268K634K3.43M972K1.01M565K209K
Other Income/Expense-319K-1.05M-34.62M1.39M5.05M5.85M9.6M
Pretax Income
-6.58M▲ 0%
-14.35M▼ 118.0%
-109.86M▼ 665.4%
-105.36M▲ 4.1%
-110.47M▼ 4.8%
-103.04M▲ 6.7%
-115.11M▼ 11.7%
Pretax Margin %-319.61%-300.27%-2297.34%-1833.39%-1931.9%-2272.52%-4111.21%
Income Tax00-8.9M-461K100K70K69K
Effective Tax Rate %0%0%8.1%0.44%-0.09%-0.07%-0.06%
Net Income
-6.58M▲ 0%
-14.35M▼ 118.0%
-100.96M▼ 603.4%
-104.9M▼ 3.9%
-110.57M▼ 5.4%
-103.11M▲ 6.7%
-115.18M▼ 11.7%
Net Margin %-319.61%-300.27%-2111.25%-1825.37%-1933.65%-2274.06%-4113.68%
Net Income Growth %--118%-603.41%-3.91%-5.4%6.75%-11.71%
Net Income (Continuing)-6.58M-14.35M-100.96M-104.9M-110.57M-103.11M-115.18M
Discontinued Operations0000000
Minority Interest0000000
EPS (Diluted)
-0.07▲ 0%
-0.54▼ 632.7%
-1.11▼ 105.6%
-1.15▼ 3.6%
-1.20▼ 4.3%
-0.94▲ 21.7%
-0.84▲ 10.6%
EPS Growth %--632.7%-105.56%-3.6%-4.35%21.67%10.64%
EPS (Basic)-0.07-0.54-1.11-1.15-1.20-0.94-0.84
Diluted Shares Outstanding92.25M92.25M92.65M90.85M92.03M110.24M136.78M
Basic Shares Outstanding92.25M92.25M92.65M90.85M92.03M110.24M136.78M
Dividend Payout Ratio-------

ABSI Balance Sheet

Absci Corporation (ABSI) balance sheet — assets, liabilities & shareholders' equity

Line itemDec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25
Total Current Assets13.65M73.23M273.08M186.86M120.58M133.83M149.57M
Cash & Short-Term Investments13.09M69.87M252.57M164.43M97.66M112.42M144.29M
Cash Only13.09M69.87M252.57M59.95M72.36M41.21M20.02M
Short-Term Investments000104.48M25.3M71.21M124.27M
Accounts Receivable222K1.59M1.43M1.55M2.19M00
Days Sales Outstanding39.34121.72108.7798.44139.73--
Inventory0010.51M15.02M000
Days Inventory Outstanding--86.0693.08---
Other Current Assets000020.73M21.41M5.28M
Total Non-Current Assets5.82M15.34M153.12M134.15M96.72M79.78M66.72M
Property, Plant & Equipment5.01M13.38M58.65M58.04M45.82M33.13M23.77M
Fixed Asset Turnover0.41x0.36x0.08x0.10x0.12x0.14x0.12x
Goodwill0021.34M21.34M000
Intangible Assets283K054.99M51.62M48.25M44.88M41.51M
Long-Term Investments790K016.84M1.86M000
Other Non-Current Assets531K1.95M18.14M-16.38M2.65M1.76M1.44M
Total Assets
19.47M▲ 0%
88.57M▲ 354.9%
426.19M▲ 381.2%
321.01M▼ 24.7%
217.3M▼ 32.3%
213.61M▼ 1.7%
216.3M▲ 1.3%
Asset Turnover0.11x0.05x0.01x0.02x0.03x0.02x0.01x
Asset Growth %-354.88%381.2%-24.68%-32.31%-1.7%1.26%
Total Current Liabilities3.47M10.1M33.86M30.27M29.56M28.66M22.77M
Accounts Payable268K2.12M8.38M2.41M1.5M3.53M2.76M
Days Payables Outstanding-67.4768.6414.9511.5320.6285.67
Short-Term Debt1.2M1.53M2.4M2.95M3.26M2.73M873K
Deferred Revenue (Current)780K01.35M445K3.17M1.12M739K
Other Current Liabilities02.63M0012.75M12.75M0
Current Ratio3.94x7.25x8.07x6.17x4.08x4.67x6.57x
Quick Ratio3.94x7.25x7.75x5.68x4.08x4.67x6.57x
Cash Conversion Cycle--126.19176.58---
Total Non-Current Liabilities57.16M11.47M26.23M16.32M11.56M5.82M4.08M
Long-Term Debt1.75M4.14M1.12M7.98M4.66M1.26M3.5M
Capital Lease Obligations2.38M6.58M12.2M8.07M5.64M4.43M2.62M
Deferred Tax Liabilities00743K238K186K00
Other Non-Current Liabilities53.03M749K12.16M35K109K133K1.02M
Total Liabilities60.63M21.56M60.09M46.59M41.12M34.48M26.85M
Total Debt6.02M14.5M20.01M22.98M15.88M10.11M5.3M
Net Debt-7.07M-55.37M-232.56M-36.97M-56.48M-31.11M-14.72M
Debt / Equity-0.22x0.05x0.08x0.09x0.06x0.03x
Debt / EBITDA-------
Net Debt / EBITDA-------
Interest Coverage-23.57x-21.64x-21.66x-109.83x-92.75x-190.24x-596.74x
Total Equity
-41.16M▲ 0%
67M▲ 262.8%
366.11M▲ 446.4%
274.41M▼ 25.0%
176.18M▼ 35.8%
179.13M▲ 1.7%
189.45M▲ 5.8%
Equity Growth %-262.8%446.39%-25.05%-35.8%1.68%5.76%
Book Value per Share-0.450.733.953.021.911.621.39
Total Shareholders' Equity-41.16M67M366.11M274.41M176.18M179.13M189.45M
Common Stock2K2K9K9K9K12K15K
Retained Earnings-41.38M-90.06M-191.03M-295.93M-406.5M-509.6M-624.78M
Treasury Stock0000000
Accumulated OCI-52.76M0-13K-120K-37K-4K591K
Minority Interest0000000

ABSI Cash Flow Statement

Absci Corporation (ABSI) cash flow — operating, investing & free cash flow history

Line itemDec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25
Cash from Operations-6.03M-10.97M-60.6M-81.34M-64.64M-72.4M-92.92M
Operating CF Margin %-292.82%-229.5%-1267.21%-1415.33%-1130.4%-1596.87%-3318.75%
Operating CF Growth %--81.86%-452.4%-34.23%20.54%-12.02%-28.35%
Net Income-6.58M-14.35M-100.96M-104.9M-110.57M-103.11M-115.18M
Depreciation & Amortization491K1.13M6.65M13.1M14M13.39M11.74M
Stock-Based Compensation42K420K10.61M12.54M11.42M19.45M18.32M
Deferred Taxes00-8.9M-505K-52K00
Other Non-Cash Items108K824K35.15M-30K19.05M-1.77M-8.23M
Working Capital Changes-89K1.01M-3.15M-1.54M1.52M-368K423K
Change in Receivables-102K-1.37M230K-148K-666K2.24M0
Change in Inventory0000000
Change in Payables82K903K1.57M-533K-786K2.03M1.09M
Cash from Investing-1.09M-2.17M-67.38M-126.98M81.94M-41.58M-50.16M
Capital Expenditures-1.1M-2.18M-38.05M-16.18M-860K-404K-1.11M
CapEx % of Revenue53.3%45.63%795.63%281.45%15.04%8.91%39.54%
Acquisitions00-28.13M-8M001.31M
Investments-------
Other Investing9K10K0783K254K939K0
Cash from Financing12.71M70.97M336.19M5.24M-4.48M82.53M105.95M
Debt Issued (Net)2.38M1.64M120.85M4.58M-5.34M-4.03M-3.2M
Equity Issued (Net)10.33M69.33M215.34M656K862K86.56M109.14M
Dividends Paid0000000
Share Repurchases0000000
Other Financing0000000
Net Change in Cash
5.58M▲ 0%
57.83M▲ 935.5%
208.22M▲ 260.0%
-203.08M▼ 197.5%
12.82M▲ 106.3%
-31.45M▼ 345.2%
-37.14M▼ 18.1%
Free Cash Flow
-7.13M▲ 0%
-13.15M▼ 84.4%
-98.64M▼ 650.1%
-97.51M▲ 1.1%
-65.5M▲ 32.8%
-72.81M▼ 11.2%
-94.03M▼ 29.2%
FCF Margin %-346.12%-275.13%-2062.84%-1696.78%-1145.44%-1605.78%-3358.29%
FCF Growth %--84.45%-650.09%1.15%32.83%-11.16%-29.15%
FCF per Share-0.08-0.14-1.06-1.07-0.71-0.66-0.69
FCF Conversion (FCF/Net Income)0.92x0.76x0.60x0.78x0.58x0.70x0.81x
Interest Paid202K508K652K895K970K561K0
Taxes Paid0000000

ABSI Key Ratios

Absci Corporation (ABSI) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric2019202020212022202320242025
Return on Equity (ROE)--111.07%-46.62%-32.76%-49.08%-58.04%-62.5%
Return on Invested Capital (ROIC)---77.73%-43.16%-48.52%-61.01%-57.96%
Gross Margin100%-139.5%-832.37%-925.02%-731.88%-1277.57%-319.36%
Net Margin-319.61%-300.27%-2111.25%-1825.37%-1933.65%-2274.06%-4113.68%
Debt / Equity-0.22x0.05x0.08x0.09x0.06x0.03x
Interest Coverage-23.57x-21.64x-21.66x-109.83x-92.75x-190.24x-596.74x
FCF Conversion0.92x0.76x0.60x0.78x0.58x0.70x0.81x
Revenue Growth-132.04%0.04%20.18%-0.5%-20.71%-38.24%

ABSI SEC Filings & Documents

Absci Corporation (ABSI) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Mar 24, 2026·SEC

Material company update

Mar 6, 2026·SEC

Material company update

Jan 14, 2026·SEC

10-K Annual Reports

4
FY 2026

Mar 24, 2026·SEC

FY 2025

Mar 18, 2025·SEC

FY 2024

Mar 21, 2024·SEC

10-Q Quarterly Reports

6
FY 2025

Nov 12, 2025·SEC

FY 2025

Aug 12, 2025·SEC

FY 2025

May 13, 2025·SEC

ABSI Frequently Asked Questions

Absci Corporation (ABSI) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Absci Corporation (ABSI) reported $2.8M in revenue for fiscal year 2025. This represents a 36% increase from $2.1M in 2019.

Absci Corporation (ABSI) saw revenue decline by 38.2% over the past year.

Absci Corporation (ABSI) reported a net loss of $115.2M for fiscal year 2025.

Dividend & Returns

Absci Corporation (ABSI) has a return on equity (ROE) of -62.5%. Negative ROE indicates the company is unprofitable.

Absci Corporation (ABSI) had negative free cash flow of $94.0M in fiscal year 2025, likely due to heavy capital investments.

Explore More ABSI

Absci Corporation (ABSI) financial analysis — history, returns, DCA and operating performance tools

Total Return Calculator

Historical returns with dividends reinvested

→

DCA Calculator

Dollar cost averaging vs lump sum

→

Dividend History

Yield, growth, payout safety & DRIP

→

Earnings History

EPS trends, net income & profitability

→

Price History

Long-term charts & historical price data

→

Revenue History

Sales growth patterns & revenue breakdown

→

Financial Ratios

30 years of market, efficiency and balance-sheet ratios

→

Valuation

DCF intrinsic value, peer multiples & estimates

→
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screener
  • Themes
  • Market Valuation
  • Valuation
  • Compare
  • Total Return
  • DCA Calculator
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Follow @VCPScanner on X

Get weekly stock ideas — free

© 2026 VCP Scanner. All rights reserved.
About·Privacy Policy·Terms of Service
Not financial advice. Do your own research.